Amylin Pharmaceuticals (AMLN) Q3 2011 Earnings Call October 19, 2011 5:00 pm ET Executives Mark G. Foletta - Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Finance Vincent P. Mihalik - Chief Commercial Officer and Senior Vice President of Sales & Marketing Michael York - Senior Director of IR Dan Bradbury - Chief Executive Officer, President, Director and Member of Risk Management & Finance Committee Analysts David Friedman - Morgan Stanley, Research Division Cory William Kasimov - JP Morgan Chase & Co, Research Division Salim Syed Terence C. Flynn - Goldman Sachs Group Inc., Research Division Thomas Wei - Jefferies & Company, Inc., Research Division Unknown Analyst - M. Ian Somaiya - Piper Jaffray Companies, Research Division Kumaraguru Raja Catherine J. Arnold - Crédit Suisse AG, Research Division PresentationOperator
Welcome to the Amylin Pharmaceuticals Q3 2011 Earnings Call. [Operator Instructions] This conference is being recorded. If you have any objections, please disconnect at this time. I would like to introduce your host, Michael York, Senior Director, Investor Relations. Sir, you may begin. Michael York Good afternoon, and welcome to Amylin Pharmaceuticals Quarterly Update Conference Call. We've uploaded a presentation to accompany this conference call that provides additional background on the quarter. This afternoon's discussion will contain forward-looking statements that involve risk and uncertainties. These risk and uncertainties are outlined in today's press release, the website presentation and in our recent filings with the Securities and Exchange Commission. Our actual results could differ materially from what is discussed during today's call. A reconciliation of all non-GAAP financial measures can be found at the end of the website presentation.